In recent years, the retinitis pigmentosa market is anticipated to grow rapidly during the forecast period. According to researchers, a total of 30,000 to 50,000 people are suffering from retinitis pigmentosa. Because there is no cure for retinitis pigmentosa, most persons who are affected by the hereditary ailment move to the severe stage of the disease. It has, however, created an opening for new medicines and treatments. Manufacturers from the ophthalmology sector are currently investigating a novel strategy known as optogenetics, which includes gene therapy to restore vision. It aids the ability of cells, particularly ganglion cells, to respond to light following the degeneration of rod and cone cells.
